DFTX Chief Commercial Officer Matthew Wiley Buys 62,500 Shares

Executive Buying at Definium Therapeutics

Definium Therapeutics, Inc. recently saw notable insider activity as top leaders adjusted their holdings in the clinical biopharmaceutical firm. On June 22, 2026, Chief Commercial Officer Matthew Wiley picked up 62,500 shares. Chief Executive Officer Robert Barrow also acquired 375,000 shares on the same date, signaling internal support as the firm develops treatments for brain health disorders.

Recent Insider Transactions

The June transactions weren't limited to purchases. Just a few days later on June 25, 2026, several executives parted with portions of their holdings through pre-arranged trading plans. Chief Financial Officer Brandi Roberts sold 3,013 shares, while Matthew Wiley also disposed of 2,867 shares at an average price of $45.03 for a total of $129,101.01. Chief Legal Officer Mark Sullivan let go of 13,008 shares valued at $585,750.24, and Chief Medical Officer Daniel Karlin offloaded 10,035 shares worth $451,876.05 at that same $45.03 price point.

Stock Price and Market Context

Trading on the NasdaqGS under the ticker DFTX, the company's shares recently changed hands around $36.67. The equity has experienced a wide trading band over the past year, dropping as low as $9.35 while reaching a peak of $49.70. Moving averages place the 50-day line at $42.28 and the 200-day line at $26.27. With a market value of roughly $5.28 billion, the firm carries a forward looking profile common among clinical-stage drug developers.

Analysts Set New Price Targets

Wall Street firms maintain an upbeat outlook on the company's pipeline progress. On October 9, 2026, JP Morgan initiated coverage with an Overweight rating and an $84.00 price target. Canaccord Genuity maintained a Buy rating on September 15, 2026, lifting its target to $78.00 from $64.00, while Baird kept an Outperform rating on the same day with a target moved to $79.00 from $75.00. Earlier in September, HC Wainwright & Co. and Needham both reiterated Buy ratings with targets of $70.00 and $66.00 respectively. RBC Capital maintained an Outperform rating at $66.00 on September 11, 2026. B of A Securities initiated coverage on August 18, 2026, with a Buy rating and a $75.00 target, and Maxim Group maintained a Buy rating on August 14, 2026, raising its target to $55.00 from $50.00. Overall, the seventeen covering analysts carry a strong buy consensus with a mean target of $71.65.

Pipeline Focus in Brain Health

Based in New York, New York, Definium Therapeutics focuses on creating novel treatments for conditions affecting brain health. Its lead product candidate, DT120, is currently in phase 3 clinical trials for generalized anxiety disorder and major depressive disorder. Another candidate, DT402, operates as an R-enantiomer of MDMA and is undergoing phase 2a trials for autism spectrum disorder. The enterprise previously operated under the name Mind Medicine Inc. before rebranding in January 2026.

What to Watch at Definium Therapeutics, Inc.

Market participants will look toward the company's next financial results release, scheduled for November 5, 2026, to monitor trial updates and corporate spending. Because insider transactions follow specific reporting rules, additional regulatory filings will provide further clarity on executive positioning as the year progresses.